Pacific Biosciences of California (NASDAQ:PACB) Insider Sells $55,639.70 in Stock

Pacific Biosciences of California, Inc. (NASDAQ:PACB) insider Michele Farmer sold 35,215 shares of Pacific Biosciences of California stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $1.58, for a total transaction of $55,639.70. Following the completion of the transaction, the insider directly owned 234,044 shares of the company’s stock, valued at approximately $369,789.52. This trade represents a 13.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Michele Farmer also recently made the following trade(s):

• On Wednesday, February 18th, Michele Farmer sold 14,952 shares of Pacific Biosciences of California stock. The shares were sold at an average price of $1.63, for a total transaction of $24,371.76.

Pacific Biosciences of California Stock Performance

NASDAQ:PACB traded up $0.05 during mid-day trading on Thursday, hitting $1.68. The stock had a trading volume of 4,308,048 shares, compared to its average volume of 7,583,859. Pacific Biosciences of California, Inc. has a twelve month low of $0.85 and a twelve month high of $2.73. The company has a debt-to-equity ratio of 17.88, a quick ratio of 5.40 and a current ratio of 6.24. The stock has a market cap of $507.21 million, a price-to-earnings ratio of -0.91 and a beta of 2.27. The company’s 50 day simple moving average is $2.02 and its 200 day simple moving average is $1.77.

Pacific Biosciences of California (NASDAQ:PACB) last posted its earnings results on Thursday, February 12th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.07. Pacific Biosciences of California had a negative return on equity of 251.75% and a negative net margin of 341.47%.The business had revenue of $44.65 million for the quarter, compared to analyst estimates of $44.60 million. On average, equities research analysts forecast that Pacific Biosciences of California, Inc. will post -0.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on PACB shares. Stephens lifted their target price on shares of Pacific Biosciences of California from $1.80 to $2.00 and gave the stock an “overweight” rating in a report on Monday, November 10th. Barclays boosted their price objective on Pacific Biosciences of California from $1.50 to $2.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pacific Biosciences of California in a research report on Thursday, January 22nd. Finally, Piper Sandler lifted their price target on Pacific Biosciences of California from $1.50 to $2.00 and gave the stock a “neutral” rating in a report on Tuesday, November 11th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $2.20.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in PACB. Invesco Ltd. boosted its stake in shares of Pacific Biosciences of California by 29.5% in the fourth quarter. Invesco Ltd. now owns 1,433,011 shares of the biotechnology company’s stock valued at $2,680,000 after buying an additional 326,238 shares during the period. Mercer Global Advisors Inc. ADV increased its stake in Pacific Biosciences of California by 47.9% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 20,663 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 6,695 shares during the period. XTX Topco Ltd raised its holdings in Pacific Biosciences of California by 5,001.3% in the 4th quarter. XTX Topco Ltd now owns 628,222 shares of the biotechnology company’s stock valued at $1,175,000 after acquiring an additional 615,907 shares in the last quarter. Polymer Capital Management US LLC bought a new stake in shares of Pacific Biosciences of California during the 4th quarter valued at $70,000. Finally, Engineers Gate Manager LP acquired a new stake in shares of Pacific Biosciences of California during the 4th quarter worth $40,000.

Key Headlines Impacting Pacific Biosciences of California

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: Management will participate in a TD Cowen health-care conference fireside chat on March 2, providing a near-term investor event where the company may update guidance, commercialization progress, or product cadence — a potential catalyst if management delivers constructive news. Read More.
• Neutral Sentiment: Despite the sales, insiders retain large holdings after the transactions (final reported post-sale holdings: Michele Farmer ~219k shares; Christian O. Henry ~2.67M shares; Oene Mark Van ~1.74M shares), which may signal liquidity-taking rather than full exits. (See SEC filings below for details.)
• Negative Sentiment: Heavy insider selling reported Feb. 17–18: combined sales by multiple executives totaled roughly 707,731 shares for about $1.13M. Notable filings: Christian O. Henry sold ~472,667 shares across two trades, Michele Farmer sold ~50,167 shares, and Oene Mark Van sold ~184,897 shares — each reducing their stakes by mid-single to low-double-digit percentages. Large, clustered insider sales can raise investor concern about near-term outlook or signal personal diversification, and may pressure sentiment until management commentary clarifies reasons. SEC filings: Christian O. Henry Read More.; Michele Farmer Read More.; Oene Mark Van Read More..

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.